×
About 2,380 results

ALLMedicine™ Angiosarcoma Center

Research & Reviews  866 results

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
https://clinicaltrials.gov/ct2/show/NCT05026736

Jan 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of sintilimab in subjects with angiosarcoma (progression- free rate PFR at 9 cycles by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1). SECONDARY OBJECTIVE: I. To evaluate the objective res...

Multidetector CT findings of primary pleural angiosarcoma : a systematic review, an add...
https://doi.org/10.1186/s40644-021-00435-1 10.1097/00000658-194309000-00014 10.1016/S1010-7940(98)00211-5 10.1056/NEJM198704023161423 10.1016/j.chest.2015.12.022 10.1093/icvts/ivt269 10.1055/s-2007-1012020 10.1016/S0003-4975(99)00073-9 10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z
Cancer Imaging : the Official Publication of the Internat... Gil BM, Chung MH et. al.

Jan 14th, 2022 - To demonstrate and analyze the relatively common imaging findings in this rare primary pleural angiosarcoma (PPA). Three cases of PPA, proven by video-assisted thoracic surgery biopsies are retrospectively reviewed. Patients were all male. Age ran...

Anastomosing Hemangioma on 68Ga-DOTATATE PET/CT: A Potential Pitfall.
https://doi.org/10.1097/RLU.0000000000003984
Clinical Nuclear Medicine; Chua WM, Hoe KMJ et. al.

Jan 13th, 2022 - Anastomosing hemangioma (AH) is a rare benign vascular lesion that primarily involves the genitourinary tract. Cases have also rarely been reported in other organs. AH is often discovered incidentally and resembles angiosarcoma histologically. On ...

see more →

Clinicaltrials.gov  17 results

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
https://clinicaltrials.gov/ct2/show/NCT05026736

Jan 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of sintilimab in subjects with angiosarcoma (progression- free rate PFR at 9 cycles by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1). SECONDARY OBJECTIVE: I. To evaluate the objective res...

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
https://clinicaltrials.gov/ct2/show/NCT04607200

Jan 11th, 2022 - This Phase 2, open-label study is designed to examine the efficacy and safety of single-agent AGEN2034 and combination AGEN2034 + AGEN1884 in patients with recurrent, inoperable or metastatic AS. Three cohorts will be enrolled into 2 Parts of the ...

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
https://clinicaltrials.gov/ct2/show/NCT03860272

Jan 10th, 2022 - This Phase 1/2 study will enroll up to approximately 86 evaluable adult subjects with refractory cancer (solid tumors) regardless of diagnosis. Subjects may be enrolled into the following cohorts: Cohort 1: AGEN1181 every 3 weeks at 0.1, 0.3, 1, 2...

A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma
https://clinicaltrials.gov/ct2/show/NCT04996004

Dec 1st, 2021 - This trial will be conducted in 2 phases: Phase I (Dose Escalation of TTI-621 in combination with doxorubicin) and Phase II (Dose Expansion of TTI-621 in combination with doxorubicin). Phase I (Dose Escalation of TTI-621 in combination with doxoru...

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
https://clinicaltrials.gov/ct2/show/NCT03277924

Nov 18th, 2021 - Cohorts 1-6: COHORT 1 - Dedifferentiated Chondrosarcoma (DDCS): For DDCS sample size is obtained for the primary endpoint of 6-month progression-free survival rate, estimated accrual 24 months. A 6-m PFSR of 40% will be considered not promising wh...

see more →

News  57 results

Dr. Meyer on Standard Treatment Options in Cardiac Angiosarcoma
https://www.onclive.com/view/dr-meyer-on-standard-treatment-options-in-cardiac-angiosarcoma

Jan 14th, 2022 - Christian Frederick Meyer, MD, PhD, MS, assistant professor of oncology, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses standard treatment options in cardiac angiosarcoma. As with most sarco...

Putting the Extremely Rare Cardiac Angiosarcoma in the Spotlight
https://www.onclive.com/view/putting-the-extremely-rare-cardiac-angiosarcoma-in-the-spotlight

Dec 21st, 2021 - Cardiac angiosarcoma is an exceptionally rare cancer that has become national news because of the recent death of acclaimed fashion designer, Virgil Abloh. He was 41 years old when he died in November 2021, following a 2-year battle with the disea...

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts
https://www.onclive.com/view/key-advances-in-sarcoma-lead-to-more-personalized-medicine-efforts

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

FDA Supports Continued Development of Oral Paclitaxel/Encequidar in Metastatic Breast Cancer
https://www.onclive.com/view/fda-supports-continued-development-of-oral-paclitaxel-encequidar-in-metastatic-breast-cancer

Jul 6th, 2021 - Athenex, Inc. held a Type A meeting with the FDA to discuss the deficiencies raised in the complete response letter (CRL) issued in March 2021 for the new drug application for oral paclitaxel plus encequidar in the treatment of patients with metas...

Soft Tissue Sarcoma: Unmet Needs
https://www.onclive.com/view/soft-tissue-sarcoma-unmet-needs

Apr 2nd, 2021 - Transcript: Neeta Somaiah, MD: I think that’s a good transition point to talk about what you think are the biggest unmet needs in patients with sarcoma. Again, I know this is a broad statement, and I’m sure there are unmet needs for patients wi...

see more →

Patient Education  12 results see all →